INTRODUCTION {#S3}
============

In mammals, specific segments of several large arteries including the aorta, pulmonary arteries, carotid arteries, and right subclavian artery derive from transient embryonic blood vessels termed pharyngeal arch arteries (PAAs) ([@R18]; [@R25]; [@R31]). Although initially bilateral, the PAAs undergo extensive remodeling, a process that creates the asymmetric pattern present at birth. Defects in the formation, maintenance, or remodeling of the PAAs result in congenital cardiovascular malformations, including interrupted aortic arch type B (IAA-B), aberrant origin of the right subclavian artery (ARSA), and right aortic arch (RAA). While sig-nificant progress has been made in understanding the molecular pathways required for proper PAA maintenance and remodeling ([@R11]), relatively little is known regarding the genetic control of PAA establishment as the cellular events, including the molecular characteristics, timing, and location of progenitor cell specification and angioblast commitment, preceding the initiation of blood flow were only recently described ([@R1]; [@R14]; [@R18]; [@R25]; [@R31]).

The zebrafish model organism allows for unparalleled real-time visualization and genetic dissection of PAA formation, a process that has been highly conserved throughout vertebrate evolution ([@R1]; [@R11]; [@R14]; [@R23]). Prior work in zebrafish demonstrated that PAAs 3--6 arise in a cranial to caudal manner by vas-culogenesis ([@R1]), the de novo differentiation of new endothelial cells from an undifferentiated progenitor population. Specifically, small clusters of *tie1*^+^ angioblasts appear in pharyngeal arches 3--6 and subsequently undergo angiogenic sprouting to give rise to patent vessels that support blood flow. This vasculogenic mechanism for PAA development was later reported to be conserved in mice ([@R14]). Unlike in higher vertebrates, the zebrafish PAAs are not remodeled but mature instead into the gill circulation ([@R9]). Despite these later differences, the early anatomic configurations of the PAAs in zebrafish and mammals are virtually indistinguishable ([@R1]; [@R8]; [@R9]; [@R18]; [@R23]), suggesting that the biological determinants of PAA establishment are also likely to be conserved.

In 2013, we reported that the embryonic source of *tie1*^+^ PAA angioblasts are *nkx2.5*^+^ progenitor cells that are specified in the zebrafish anterior lateral plate mesoderm ([@R23]). Using in situ hybridization, Kaede-mediated fate mapping, and Cre/loxP lineage tracing, we learned that *nkx2.5^+^* progenitor clusters initiate *tie1* expression sequentially in an anterior to posterior direction. After a transient period of overlap, *nkx2.5* expression is downregulated while *tie1* is maintained throughout PAA morphogenesis. A recent report in zebrafish highlighted the importance of Stat4 in this process ([@R15]). However, the molecular signals that trigger this progenitor to angioblast transition remain unknown.

To identify molecular pathways required for PAA development, we performed a small-molecule screen for suppressors of *tie1*^+^ angioblast formation in zebrafish embryos. Among several hits, a predicted antagonist of *TGF-β* signaling was identified. Through follow-up studies, we identify *TGF-β* signaling as necessary and sufficient for stimulating PAA progenitor cell differentiation toward the angioblast lineage.

RESULTS {#S4}
=======

A Chemical Screen in Zebrafish Implicates TGF-*β* Signaling in PAA Morphogenesis {#S5}
--------------------------------------------------------------------------------

To identify factors and pathways required for PAA morphogenesis, we screened 1,235 biologically active small molecules for suppressors of *tie1^+^* PAA angioblast development in zebrafish embryos ([Figure S1](#SD1){ref-type="supplementary-material"}). Immediately following gastrulation (bud stage, 10 hpf), groups of 15--20 wild-type embryos were exposed in 48-well plates to individual chemicals diluted to a final concentration of 10 *μ*M. Embryos were fixed at 36--38 hpf, processed for in situ hybridization with a *tie1* riboprobe, and evaluated for angioblast number. We used the average number of clusters observed unilaterally per embryo per well to score each compound for suppressor activity. The negative control, DMSO, routinely scored between 2.8 and 3.0. Compounds with scores less than or equal to 1.5 were categorized as hits. From this effort, we identified 49 suppressors (4.0% of total) that did not grossly compromise blood vessel development elsewhere in the embryo ([Table 1](#T1){ref-type="table"}; [Figures 1A](#F1){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). The remaining compounds scored greater than 1.5 (90.8%; n = 1,121) or caused early embryonic lethality (5.2%; n = 65; [Figure 1A](#F1){ref-type="fig"}).

We binned the small molecules identified by our primary screen into broad categories based on biological activity ([Table 1](#T1){ref-type="table"}). Compounds targeting receptors or downstream effectors for multiple pathways were identified as were bioactive lipids and modulators of lipid metabolism or signaling. We identified two antagonists predicted to inhibit retinoic acid signaling, a genetic pathway previously implicated in PAA morphogenesis in mice ([@R14]). Although secondary screening will be required to validate hits from the primary screen, our efforts uncover several candidate pathways deserving of further attention.

One suppressor identified by our screen, CB 41227199 ([Table 1](#T1){ref-type="table"}), is predicted to antagonize the *TGF-β* type I receptor ALK5 ([Figures 1B and 1C](#F1){ref-type="fig"}). To corroborate that blocking ALK5 inhibits PAA angioblast formation, we treated embryos between 20 and 36--38 hpf with increasing doses of two selective ALK5 antagonists, LY-364947 and SB-505124 ([@R13]; [@R32]; [@R36]). Both chemicals significantly reduced the number of *tie1*^+^ angioblast clusters in a dose-dependent fashion ([Figures 1D--1H](#F1){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). LY-364947 also decreased the expression of *kdrl* ([Figures 1I--1M](#F1){ref-type="fig"}), a second marker of PAA angioblasts. When clusters did form, they were often smaller and/or failed to sprout. These data uncover *TGF-β* signaling as a pathway required for PAA angioblast cluster formation.

To determine whether phenotypic recovery and/or compensatory angiogenesis from the lateral dorsal aorta (LDA) ([@R19]) might permit chemically treated embryos to form patent PAAs despite the angioblast phenotype, we analyzed LY-364947-treated embryos for PAA defects at 60 hpf using fluores-cent reporters of the endothelial (*kdrl:GFP*) ([@R10]) and red blood cell (*gata1:dsRed*) ([@R30]) lineages. Whereas control embryos exhibited robust blood flow through PAAs 3--6 ([Figures 1N and 1Q](#F1){ref-type="fig"}), significant reductions in patent vessel number were observed in LY-364947-treated animals ([Figures 1O--1Q](#F1){ref-type="fig"}). Approximately one-quarter lacked PAAs altogether with many showing evidence of incomplete compensatory angiogenesis. Consistent with our screening criteria, the vascular defects in LY-364947-treated embryos were localized specifically to the pharyngeal arches. The head and body vasculature appeared largely unaffected by LY-364947 treatment and blood flow through the cranial vessels remained intact ([Figure S2](#SD1){ref-type="supplementary-material"}). Importantly, we ruled out a pharyngeal segmentation defect ([Figure S3](#SD1){ref-type="supplementary-material"}) as an indirect cause of the *tie1^+^;kdrl^+^* PAA cluster phenotype ([@R24]; [@R26]). Taken together, these data demonstrate that *TGF-β* signaling is required for PAA angioblast formation and PAA morphogenesis.

TGF-*β* Promotes the PAA Progenitor to Angioblast Transition {#S6}
------------------------------------------------------------

We considered two potential explanations for the LY-364947-mediated reduction in *tie1*^+^;*kdrl*^+^ angioblast clusters ([Figures 1D--1M](#F1){ref-type="fig"}) including failed specification of *nkx2.5^+^* PAA progenitors in the anterior lateral plate mesoderm (ALPM) ([@R23]) or a reduced capacity of progenitors to differentiate into angioblasts in the arches proper. To distinguish these possibilities, we inhibited *TGF-β* signaling during shorter intervals ([Figure 2A](#F2){ref-type="fig"}), timed to overlap with progenitor specification or differentiation, and evaluated animals for angioblast formation. *TGF-β* suppression during progenitor cell specification (10--16 hpf) did not impair *tie1*^+^ angioblast formation ([Figures 2A, 2B, 2G, and 2L](#F2){ref-type="fig"}). By contrast, *TGF-β* inhibition during progenitor cell differentiation (16 hpf^+^) effectively suppressed angioblast emergence ([Figures 2A and 2H--2L](#F2){ref-type="fig"}) compare to DMSO vehicle control ([Figures 2A, 2C--2F, and 2L](#F2){ref-type="fig"}). In fact, significant reductions in *tie1*^+^ clusters were observed in embryos treated as late as 24 and 28 hpf, which coincides temporally with the anterior to posterior wave of PAA cluster differentiation ([@R23]). Together, these data suggest that *TGF-β* pathway inhibition might impair the progenitor to angioblast transition.

To test this hypothesis directly, we evaluated *TGF-β*-suppressed animals for expression of an earlier marker of the angio-blast lineage, *etsrp,* that precedes *tie1* and *kdrl* expression ([@R23]). Dose-dependent reductions in *etsrp*^+^ cluster numbers were observed following treatment with LY-364947 ([Figures 3A--3E](#F3){ref-type="fig"}), indicating that initiation of the angio-blast program requires *TGF-β* signaling. Next, we analyzed expression of the PAA progenitor marker *nkx2.5* that disappears in a cranial to caudal sequence as *tie1* expression initiates in a reciprocal fashion ([@R23]). In control embryos at 36 hpf, we observed *nkx2.5* expression exclusively in progenitors residing in pharyngeal arch 6 because expression in arches 3--5 has downregulated by this stage ([Figure 3F](#F3){ref-type="fig"}) ([@R23]). By contrast, *TGF-β*-inhibited embryos expressed *nkx2.5* in pharyngeal arches 3--6 indicating that *nkx2.5* transcripts persisted abnormally in the anterior three arches ([Figure 3G](#F3){ref-type="fig"}). We quantified this phenotype using double transgenic embryos, \[*Tg(nkx2.5:nZsYellow)* ([@R23]); *Tg(fli1a:nEGFP)* ([@R35])\], that express fluorescent proteins in the nuclei of PAA progenitor or endothelial cells ([Figures 3H--3J](#F3){ref-type="fig"}). This analysis revealed a 3-fold increase in the number of *nkx2.5*^+^ PAA progenitor cells resulting from *TGF-β* suppression ([Figure 3J](#F3){ref-type="fig"}). These data demonstrate that *TGF-β* signaling is required for *nkx2.5^+^* PAA progenitors to differentiate into angioblasts.

TGF-*β* Signaling Components Are Expressed in the Pharynx during PAA Angioblast Differentiation {#S7}
-----------------------------------------------------------------------------------------------

To visualize the pharyngeal expression patterns of *TGF-β* pathway components, we performed in situ hybridization for five *TGF-β* ligands, four *TGF-β* receptors, and one *TGF-β* chaperone at 28 hpf, a time point immediately preceding PAA angioblast differentiation ([Figure 4](#F4){ref-type="fig"}) ([@R23]). Transcripts encoding the type I (ALK5) and type II *TGF-β* receptor paralogs were broadly distributed at varying levels throughout the pharynx ([Figures 4A--4D](#F4){ref-type="fig"}). Although expression of *TGF-β1b* did not appear robust ([Figure 4F](#F4){ref-type="fig"}), mRNAs encoding *TGF-β1a*, *2a*, *2b*, and *3* were more pronounced ([Figures 4E, 4G, 4I, and 4J](#F4){ref-type="fig"}). Specifically, *TGF-β1a* and *2b* transcripts were broadly distributed ([Figures 4E and 4I](#F4){ref-type="fig"}), while *2a* and *3* co-localized with the endodermal pouch marker *nkx2.3* ([Figures 4H and 4K](#F4){ref-type="fig"}). Transcripts encoding the *TGF-β* chaperone, Latent *TGF-β* Protein 3 (LTBP3), were also observed in the pharyngeal pouches ([Figure 4L](#F4){ref-type="fig"}). Taken together, these data suggest that multiple cell types in the pharynx are capable of producing and responding to *TGF-β* ligands during the PAA angioblast differentiation window. Moreover, the overlapping distributions of multiple receptors and ligands indicate that considerable genetic redundancy exists within the *TGF-β* signaling pathway to ensure proper PAA angioblast differentiation.

A Wave of TGF-β Signaling in the Pharynx Precedes the Differentiation of PAA Angioblasts from nkx2.5^+^ Precursors {#S8}
------------------------------------------------------------------------------------------------------------------

To better characterize the timing and location of *TGF-β* receptor activity in pharyngeal tissues during PAA development, we stained embryos for phosphorylated-Smad3 epitopes ([@R2]; [@R27]; [@R29]), prior to and during the emergence of *tie1^+^* PAA angioblast clusters. At these stages, pharyngeal arches 3--6 comprise mesodermal cores enveloped by *sox10*^+^ neural-crest-derived cells that are bounded medially by *sox17*^+^ endodermal pouches ([Figures 5A--5C](#F5){ref-type="fig"}) ([@R24]). Approximately 4 hr prior to the appearance of *tie1* expression in arch 3 (28 hpf) ([@R23]), we observed pSmad3 staining in a majority of *nkx2.5^+^* PAA progenitor cells in the same location ([Figures 5D and 5E](#F5){ref-type="fig"}). By contrast, progenitors in arch 4 were devoid of pSmad3 at this developmental stage ([Figures 5D and 5E](#F5){ref-type="fig"}). Four hours later, pSmad3 staining was observed in arch 4 progenitors ([Figures 5F and 5G](#F5){ref-type="fig"}), prior to *tie1* expression ([@R23]), but no longer in *tie1^+^* arch 3 angioblasts ([Figures 5F and 5G](#F5){ref-type="fig"}). Finally, at 36 hpf, pSmad3 was observed in arch 5 progenitors ([Figures 5H and 5I](#F5){ref-type="fig"}), prior to *tie1* expression ([@R23]), but no longer in *tie1^+^* arch 4 angio-blasts ([Figures 5H and 5I](#F5){ref-type="fig"}). These data uncover a cranial to caudal wave of *TGF-β* receptor activity in PAA progenitor cells that anticipates a subsequent wave of angioblast lineage commitment. The spatiotemporal dynamics of pSmad3 staining are consistent with *TGF-β* signaling playing a cell-autonomous role in initiating the PAA progenitor to angioblast transition. However, because additional pharyngeal lineages, including neural-crest-derived and endodermal cells, also stained positive for pSmad3 ([Figures 5D--5J](#F5){ref-type="fig"}), we cannot rule out non-cell-autonomous functions for *TGF-β* in PAA morphogenesis. As anticipated, pSmad3 epitopes were essentially non-existent in LY-364947-treated embryos ([Figures 5K--5N](#F5){ref-type="fig"}) confirming that the small molecule effectively antagonizes *TGF-β* signaling.

Premature TGF-*β* Signaling Is Sufficient to Stimulate Precocious Appearance of PAA Angioblasts {#S9}
-----------------------------------------------------------------------------------------------

To test the sufficiency of *TGF-β* signaling for initiating the PAA progenitor to angioblast transition, we utilized a previously validated transgenic strain, *Tg(hsp70:caALK5)* ([@R36]), to achieve heat-shock inducible expression of a constitutively active isoform of ALK5 beginning at 14 hpf, a time point that is 18 hr prior to angioblast emergence ([Figure 6A](#F6){ref-type="fig"}). Embryos were analyzed for either *etsrp^+^* or *tie1^+^* PAA angioblast clusters at 24 or 28 hpf, respectively, a developmental stage when \~80% of control animals are completely devoid of angioblasts ([Figures 6B, 6C, 6E, 6F, 6H, and 6I](#F6){ref-type="fig"}). Remarkably, 75% and 92% of embryos with premature *TGF-β* signaling contained one or two substantial *etsrp*^+^ and *tie1*^+^ angioblast clusters, respectively ([Figures 6D, 6G, 6H, and 6I](#F6){ref-type="fig"}). These data demonstrate that genetic activation of *TGF-β* signaling is sufficient to initiate the PAA progenitor to angioblast transition. Because pharyngeal arches 5 and 6 are not seeded with *nkx2.5*^+^ progenitor cells until after 28 hpf ([@R23]), the absence of pre-mature *tie1* expression in these arches was not surprising. Together, our data demonstrate that *TGF-β* signaling is both necessary and sufficient to drive PAA angioblast lineage commitment.

DISCUSSION {#S10}
==========

Our observations in zebrafish support a model in which *nkx2.5*^+^ PAA progenitor clusters receive a *TGF-β* signal that initiates their differentiation to the *tie1*^+^ angioblast lineage in a cranial to caudal sequence. Specifically, we witnessed a burst of active *TGF-β* signaling as detected by pSmad3 immunofluorescence in each *nkx2.5*^+^ PAA cluster just prior to angioblast lineage commitment. This differentiation event was sensitive to small-molecule inhibition of *TGF-β* signaling, demonstrating the necessity of this program for PAA morphogenesis. Most surprisingly, early activation of the ALK5 *TGF-β* receptor resulted in premature differentiation of PAA progenitor clusters, demonstrating the sufficiency of *TGF-β* signaling for driving the *tie1*^+^ angioblast fate. Because we observed pSmad3 epitopes broadly throughout the pharynx during angioblast emergence, tissue-specific requirements for *TGF-β* signaling in PAA establishment cannot be investigated until floxed alleles of *TGF-β* pathway components become available.

While *TGF-β* signaling has yet to be implicated in mammalian PAA establishment, it plays a clear role in PAA maintenance and remodeling. Specifically, mice deficient in *TGF-β2* display IAA-B and ARSA that stem from abnormal regression of the fourth PAAs ([@R17]). Similarly, IAA-B and ARSA were observed in mice with neural-crest-specific deletions of the *TGF-β* type II receptor (*TβRII*) ([@R5]) or Smad4 ([@R20]). However, because mice that are homozygous for null alleles of *TGF-β1* ([@R7]), *TβRI* ([@R12]), *TβRII* ([@R22]), Smad2 ([@R21]; [@R33]), or Smad4 ([@R34]) die prior to PAA establishment, they could not be assessed for potential defects in PAA formation. Our zebrafish data bring up the possibility that bypassing this early embryonic lethality with more refined genetic tools might reveal PAA establishment phenotypes in mice. *TGF-β* signaling is essential for extra-embryonic vasculogenesis ([@R7]; [@R22]), and the *TGF-β2* ligand was recently shown to be required and sufficient to promote endothelial cell differentiation from murine induced pluripotent stem cells (iPSCs) in culture ([@R6]). These observations, together with our zebrafish studies, provide a developmental context within which *TGF-β* might serve as a critical regulator of vasculogenesis in the mammalian embryo proper.

In summary, our small-molecule screen represents the first unbiased approach to begin dissecting the molecular basis of PAA establishment, an understudied yet important line of inquiry. Identification of the genetic programs that regulate PAA development could be leveraged to inform the development of improved preventative and/or therapeutic approaches for treating congenital cardiovascular malformations involving the aortic arch and its branches.

EXPERIMENTAL PROCEDURES {#S11}
=======================

Zebrafish Husbandry and Strains {#S12}
-------------------------------

Zebrafish were grown and maintained according to protocols approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee. The following strains were utilized: *Tg(--4.9sox10:egfp)^ba2^*([@R3]), *Tg(nkx2.5:GFP)^el83^*([@R4]), *Tg(nkx2.5:ZsYellow)^fb7^*([@R36]), *Tg(sox17:GFP)^s870^* ([@R16]), *Tg(kdrl:GFP)^la116^* ([@R10]), *Tg(gata1:DsRed)^sd2^* ([@R30]), *Tg(hsp70l:caALK5)^fb6^* ([@R36]), *Tg(nkx2.5:nZsYellow)^fb17^* ([@R23]), and *Tg(fli1a:nEGFP)^y7^* ([@R35]). Unless specified, live embryos were kept at 28.5°C and anesthetized in standard embryo media containing 0.4% tricaine (ethyl 3-aminobenzoate methanesulfonate, MS222; Sigma). *Tg(hsp70:caAlk5)* embryos were heat shocked at 37°C s for 1 hr and fixed at 24 hpf for *etsrp* and 28 hpf for *tie1* expression analysis.

Chemical Exposures {#S13}
------------------

For the small-molecule screen, zebrafish embryos were exposed to individual test compounds from tail-bud stage (10 hpf) until 36--38 hpf and evaluated by in situ hybridization for *tie1* expression in PAA clusters. Fifteen to 20 wild-type and age-matched embryos per well were arrayed into 48-well plates and exposed to test compounds diluted to 10 *μ*M. Embryos were transferred to 96-well MultiScreen-MESH Filter Plates (EMD Millipore), washed once in E3, and fixed in 4% paraformaldehyde/PBS (pH 7.4) (PFA). Dilute pronase was added overnight to facilitate removal of chorions prior to fixation. The NINDS Custom Collection 2 (320 compounds), BIOMOL ICCB Known Bioactives (415 compounds), Chembridge KinaCore (250 compounds), and Chembridge Nuclear Hormone Receptor Core (250 compounds) libraries were provided by the Institute of Chemistry and Chemical Biology (ICCB) at Harvard Medical School. Chembridge Library collection compound structures can be found using the following link and entering the compound ID number: <https://www.hit2lead.com/search.asp?db=SC&SearchPage=id>.

Dose-response curves were obtained by treating zebrafish embryos with 20--100 *μ*M SB-505124 (Sigma) or 30--70 *μ*M LY-364947 (Selleckchem) in the dark beginning at 20 hpf. In subsequent experiments, embryos were treated starting at indicated stages with 50 *μ*M LY-364947. Control embryos were exposed concurrently to equivalent amounts of DMSO. After chemical exposure, embryos were washed three to five times in E3 solution and/or fixed with 4% PFA at the indicated stages.

Zebrafish Whole-Mount In Situ Hybridization {#S14}
-------------------------------------------

Single or double whole-mount in situ hybridizations were performed in glass vials as previously described ([@R23]) or in 96-well mesh-bottom plates. Digoxygenin-labeled anti-sense RNA probes to *nkx2.3*, *nkx2.5*, *tie1*, *etsrp*, *kdrl*, *tgfbr1a*, *tgfbr1b*, *tgfbr2a*, *tgfbr2b*, *tgfb1a*, *tgfb1b*, *tgfb2a*, *tgfb2b*, *tgfb3*, and *ltbp3* were synthesized using a DIG RNA Labeling Kit (SP6/T7/T3; Roche Applied Science). A blue (NBT/BCIP) chromogenic substrate was utilized (Promega). Double in situ hybridizations were performed using anti-sense fluorescein-labeled RNA probes to *nkx2.3* that were synthesized using a Fluorescein RNA Labeling Kit (SP6/T7/T3; Roche Applied Science). An orange (INT/BCIP) chromogenic substrate was utilized (Roche Applied Science).

Zebrafish Immunohistochemistry {#S15}
------------------------------

Manipulations were performed at room temperature unless otherwise stated. Embryos were fixed overnight in 4% PFA at 4°C and then washed at room temperature with PBS (pH 7.4) 0.1% Tween 20 (PBST) four times for 10 min. Embryos were incubated in a bleach solution (0.5% potassium hydroxide \[KOH\]/3% H~2~O~2~/0.1% Tween 20) in the dark until pigment was removed and washed four times for 10 min with PBST. Permeabilization was achieved by incubating embryos in PBST/0.5% Triton X-100 for 2 hr followed by incubation in block solution (5% BSA/5% goat serum in PBST) for 2 hr. Embryos were incubated with primary antibodies diluted in block solution overnight at 4°C. Embryos were washed six times for 20 min in PBST and incubated with secondary antibodies diluted in block overnight at 4°C. Secondary antibodies were removed by washing with PBST six times for 20 min prior to imaging or storage at 4°C in PBST. Primary antibodies specific for GFP (B-2 mouse monoclonal catalog number sc-9996; Santa Cruz Biotechnology), pSMAD3 (Smad3 \[phospho S423 + S425\] rabbit monoclonal antibody, catalog number ab52903, AbCam), and ZsYellow (RCFP rabbit polyclonal antibody; Clontech) were used at 1:50 dilutions. Secondary antibodies (Alexa Fluor 488 goat α-mouse immunoglobulin G \[IgG\], Alexa Fluor 555 goat α-rabbit IgG, Alexa Fluor 647 goat α-rabbit IgG \[Invitrogen\]) were used at 1:500 dilutions.

Microscopy {#S16}
----------

Live or processed embryos were imaged on a Nikon 80i compound microscope (Nikon) with Retiga 2000R high-speed charge-coupled device (CCD) camera (*QImaging*) and NIS-Elements advanced research image acquisition and analysis system (Nikon Instruments). Embryos processed for in situ hybridization were mounted on glass slides in 100% glycerol. Images of embryos processed by in situ hybridization were captured using a mounted Excelis AU600HDS HD Camera (Accu-Scope), and the resulting images were focus-stacked with Zerene Stacker Software (Build T201412212230). Confocal microscopy was performed using either a Zeiss LSM5 Pascal Laser Scanning Microscope (Carl Zeiss MicroImaging) or a Nikon A1SiR Confocal Microscope (Nikon). Live and fixed fluorescent embryos were mounted in 0.9% lo-melt agarose in glass-bottom dishes (MatTek) and covered with embryo media containing 0.4% tricaine or PBST. Live *Tg(kdrl:GFP)^la116^*;*Tg(gata1:DsRed)^sd2^* embryos were imaged and analyzed for numbers of patent PAAs in z stack confocal images using ImageJ software ([@R28]). GFP^+^ and ZsYellow^+^ nuclei in *Tg(nkx2.5:nZsYellow)^fb17^; Tg(flia:nEGFP)^y7^* embryos were counted in z stack confocal images using ImageJ software ([@R28]). *Tg(nkx2.5:GFP)^el83^* and *Tg(sox17:GFP)^s870^* embryos were fixed and immunostained for GFP and pSMAD3. z stack images acquired by confocal microscopy and analyzed with ImageJ software ([@R28]).

Statistical Analysis {#S17}
--------------------

Statistical analysis was performed with GraphPad Prism software version 7.00 for Macintosh (GraphPad). Pharyngeal angioblast cluster numbers were counted bilaterally for each embryo. The larger number was recorded and used to calculate the average number of clusters per embryo per test condition. All results are expressed as mean ± SD. Differences between control and treated groups were assessed by one-way ANOVA followed by either Dunnett's or Sidak's multiple comparisons test. The number of PAAs supporting blood flow was determined per left side of each embryo, and a chi-square test was performed using GraphPad Prism Software. The number of ZsYellow^+^ nuclei was quantified per left side of each embryo. Results are expressed as mean ± SD. An unpaired t test was performed using GraphPad Prism software. In all cases, the investigators were blinded to cohort when quantifying pharyngeal cluster numbers and patent PAA formation. All embryos were included in the assessments.
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![A Small-Molecule Screen in Zebrafish Implicates *TGF-β* Signaling in PAA Morphogenesis\
(A) 1,235 small molecules were screened for activities that suppress the formation of *tie1^+^* PAA angioblasts in zebrafish. Shown are the percentages of compounds that fell into each of three categories.\
(B and C) Left lateral views of *tie1^+^* PAA angioblast clusters in 36-hr post-fertilization (hpf) embryos treated from bud stage with DMSO (B) or 10 μM CB 41227199 (C), a predicted inhibitor of *TGF-β* signaling. The angioblast clusters are numbered as shown (B) according to the pharyngeal arches within which they form. Seven of 14 chemically treated embryos were devoid of *tie1^+^* clusters.\
(D--L) Left lateral views of (D--G) *tie1^+^* or (I--L) *kdrl^+^* PAA angioblasts in 36-hpf embryos treated from 20 hpf with DMSO or the indicated, increasing concentrations of LY-364947. The angioblast clusters that did form in LY-364947-treated embryos were smaller and/or failed to sprout (asterisks in F, G, K, and L). Scale bars, 200 μm.\
(H and M) Bar graphs showing the average number of *tie1*^+^ or *kdrl*^+^ angioblast clusters ±SD that formed in each experimental group (\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001). n = 40--50 embryos per group with a total of three biological replicates.\
(N--Q) Left lateral views of 60-hpf *Tg(kdrl:GFP),Tg(gata1:DsRed)* embryos treated from 20 hpf with DMSO (N) or LY-364947 (O and P) imaged in the green and red channels to visualize endothelium (pseudocolored magenta) and red blood cells (RBC) (pseudocolored yellow), respectively. In DMSO-treated embryos, four patent PAAs supported robust blood flow as evidenced by strong luminal RBC fluorescence (N). LY-364947-treated embryos displayed a reduced number (O; class I) or complete absence (P; class II) of patent PAAs. Asterisks in (P) highlight compensatory sprouting of endothelial cells from the LDA. (Q) Bar graph showing the percentages of DMSO (n = 30) and LY-36497-treated (n = 40) embryos with four patent PAAs (wild-type), one to two patent PAAs (class I), or zero PAAs (class II). \*\*\*p \< 0.001. No animals contained three patent PAAs. Scale bars, 25 μm.](nihms894197f1){#F1}

![*TGF-β* Signaling Is Required during PAA Progenitor Differentiation\
(A--L) Stage-specific LY-364947 exposure reveals a requirement for *TGF-β* signaling after PAA progenitor specification. (A) Schematic diagram showing drug treatment regimens designed to inhibit *TGF-β* signaling during (10--16 hr post-fertilization; hpf) and/or after (+16 hpf) progenitor specification. (B--K) Left lateral views of *tie1^+^* PAA angioblast clusters in 36-hpf embryos treated during the indicated developmental windows with DMSO or 50 μM LY-364947. The angioblast clusters that did form in LY-364947-treated embryos appeared smaller and/or failed to sprout (asterisks in H, J, and K). Scale bars, 200 *μ*m. (L) Bar graph showing the average number of *tie1^+^* angioblast clusters ±SD within each experimental group (\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001). n = 20--50 embryos per treatment group with a total of three biological replicates.](nihms894197f2){#F2}

![*TGF-β* Signaling Is Required for the PAA Progenitor to Angioblast Transition\
(A--D) Left lateral views of *etsrp^+^* PAA angioblasts in 36-hpf embryos treated from 20-hpf stage with DMSO or the indicated, increasing concentrations of LY-364947. The angioblast clusters that did form in LY-364947-treated embryos were smaller and/or failed to sprout (asterisks in C and D). Scale bars, 200 μm.\
(E) Bar graph showing the average number of *etsrp^+^* angioblast clusters ±SD within each experimental group (\*\*p \< 0.01; \*\*\*p \< 0.001). n = 40--50 embryos per treatment group with a total of four biological replicates.\
(F and G) Left lateral views of *nkx2.5^+^* PAA progenitors in 36-hpf embryos treated from 20 hpf with DMSO (F, n = 43) or LY-364947 (G, n = 38/54 with the phenotype shown, 14/54 showed a milder phenotype, 2/54 appeared normal). The line in (G) highlights persistent expression of *nkx2.5* transcripts in PAA progenitors of arches 3--6 in LY-364947-treated embryos.\
(H and I) Left lateral views of 38-hpf *Tg(fli1a:nGFP),Tg(nkx2.5:ZsYellow)* embryos treated from 20 hpf with DMSO or LY-364947, immunostained for GFP and ZsYellow, and imaged in the green and red channels to visualize PAA endothelial (pseudocolored magenta) and progenitor (pseudocolored yellow) cell nuclei, respectively.\
(J) The bar graph shows the average numbers ±SD of *nkx2.5:ZsYellow^+^* PAA progenitors in DMSO and LY-364947-treated embryos. n = 4 for both experimental groups. \*\*\*p \< 0.0001. Scale bars, 25 μm.](nihms894197f3){#F3}

![*TGF-β* Pathway Components Are Expressed in the Pharynx during PAA Angioblast Differentiation\
(A--L) Left lateral views of indicated *TGF-β* pathway component expression in 28 hr post-fertilization (hpf) embryos. (A--D) Transcripts encoding the canonical *TGF-β* receptor paralogs RIa/b and RIIa/b are broadly distributed in the pharyngeal region. (E--G, I, and J) Expression of the indicated *TGF-β* ligands in the pharynx. (H, K, and L) Double in situ hybridization highlighting overlap of indicated *TGF-β* pathway component transcripts with transcripts encoding the pharyngeal endodermal pouch marker, *nkx2.3*. (n = 30--40 embryos per in situ hybridization probe). Scale bars, 200 μm.](nihms894197f4){#F4}

![A Burst of *TGF-β* Signaling Precedes *tie1^+^* PAA Angioblast Differentiation\
(A) Cartoon of zebrafish embryo highlighting the left-side pharyngeal arches 3--6 (boxed) analyzed at higher magnifications in (B)--(N). The spatial relationships between PAA progenitors (magenta), neural-crest-derived cells (green), and endodermal pouches (gray) are shown.\
(B and C) Left-side dorsal views of 32 hr post-fertilization (hpf) *Tg(sox10:GFP)*, *Tg(nkx2.5:ZsYellow)*, or *Tg(sox17:GFP),Tg(nkx2.5:ZsYellow)* embryos immuno-stained for GFP and ZsYellow and imaged in the green and far red channels to visualize neural crest cells (pseudocolored green), endodermal pouches (pseudocolored gray), and PAA progenitor clusters (pseudocolored magenta). n = 5 for both groups.\
(D--I) Spatiotemporal dynamics of *TGF-β* signaling during PAA angioblast differentiation. Dorsal views of *Tg(nkx2.5:GFP)* embryos at the indicated developmental stages immunostained for GFP and pSMAD3 imaged in the green and far red channels to visualize PAA progenitors (pseudocolored magenta) and cells experiencing active *TGF-β* signaling (pseudocolored yellow). 28 hpf, n = 3; 32 hpf, n = 4; 36 hpf, n = 6.\
(J) Left-side dorsal views of *Tg(sox17:GFP)* embryos at 36 hpf immunostained for GFP and pSMAD3 imaged in the green and far red channels to visualize endodermal pouches (pseudocolored gray) and cells active for *TGF-β* signaling (pseudocolored yellow), n = 2.\
(K--N) Left-side dorsal views of *Tg(nkx2.5:GFP)* embryos at 32 hpf immunostained for GFP (pseudocolored magenta) and pSMAD3 (pseudocolored yellow) following treatment from 20 hpf with DMSO (K and L; n = 3) or 50 μM LY-364947 (M and N; n = 8). Scale bars, 25 μm.](nihms894197f5){#F5}

![Premature *TGF-β* Signaling Induces Precocious Differentiation of *tie1^+^* PAA Angioblasts\
(A) Experimental design for heat-shock-mediated (HS^+^) induction of *TGF-β* signaling in *Tg(hsp70:caAlk5)* embryos at 14 hpf (10 somites stage) followed by analysis of *etsrp*^+^ and *tie1^+^* PAA angioblasts at 24 or 28 hr post-fertilization (hpf), respectively. Transgenic embryos not exposed to heat shock (HS^--^, Tg^+^) and heat shocked wild-type embryos (HS^+^, Tg--) were used as controls.\
(B--G) Left lateral images of 24-hpf (B--D) or 28-hpf (E--G) control (B, C, E, and F) and experimental (D and G) embryos. Two large *etsrp*^+^ or *tie1^+^* PAA angioblast clusters are visible in (D) and (G), respectively, whereas the majority of control embryos (B, C, E, and F) lacked PAA angioblasts at this stage. Scale bars, 200 μm.\
(H and I) Bar graphs showing the average number of *etsrp*^+^ or *tie1^+^* angioblast clusters ±SD within each experimental group (\*p \< 0.05; \*\*p \< 0.01). n = 40--50 embryos per group with a total of three biological replicates.](nihms894197f6){#F6}

###### 

Small Molecules Identified by Chemical Screening in Zebrafish for Suppressors of PAA Angioblast Differentiation

  Category                                                        Compounds
  --------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kinase and phosphatase inhibitors                               
   TGF-β receptor inhibitor                                       CB 41227199[a](#TFN2){ref-type="table-fn"}
   Protein kinase A and B inhibitor                               CB 97929926
   Protein kinase C inhibitor                                     calphostin C
   Thymidine kinase inhibitor                                     CB 17846240
   Cyclin-dependent kinase inhibitors                             CB 42005171, CB 20372475, CB 14126598
   IκB kinase inhibitors                                          CB 15143266, CB 28324237
   c-Jun N-terminal kinase 3 inhibitor                            CB 34431373
   ERBB2 kinase inhibitor                                         tyrphostin AG-825
   RAF kinase inhibitor                                           CB 14171361
   SRC kinase inhibitor                                           CB 14280993
   CD45 phosphatase inhibitor                                     RWJ-60475-(AM)3
  Bioactive lipids, modulators of lipid metabolism or signaling   
   Omega-3, 6, 9 fatty acids                                      eicosatrienoic acid (20:3 n-3) (11,14,17-ETE) docosahexenoic (22:6, n-3) (4,7,10,13,16,19-DHA) arachidonic acid (20:4, n-6) (5,8,11,14-AA) eicosatriynoic acid (20:3, n-9) (5,8,11-ETI)
   Cyclooxygenase inhibitors                                      indomethacin, indoprofen
   Lipoxygenase metabolite                                        12(R) = HETE
   Prostaglandins                                                 PGD2; 13,14-Dihydro-PGE1; 17-phenyl-trinor-PGE2; 9B,11A-PGF2
   Leukotriene B4 antagonist                                      U-75302
  Ion channel modulators and ionophores                           
   Potassium channel openers                                      cloxyquin, minoxidil, rottlerin
   Calcium ionophore                                              ionomycin
  Nuclear hormone receptor inhibitors                             
   Liver × receptor inhibitor                                     CB 78238822
   Retinoic acid receptor inhibitors                              CB 70700976, CB 82029493
  Other signaling modulators                                      
   Nuclear factor κB (NF-κB) inhibitor                            caffeic acid phenethyl ester
   Adenosine A~3~ receptor agonist                                IB-MECA
   Phosphodiesterase inhibitors                                   zardaverine, dyphylline
   Histamine H1 receptor antagonists                              doxylamine succinate, carbinoxamine maleate
  Antimicrobials                                                  fusidic acid, chloroxylenol, nitrofurantoin
  Other                                                           N-Acetyl-S-geranyl-L-cysteine, guanethidine sulfate, roxarsone, glucosamine hydrochloride, guaifenesin, lactulose, alrestatin

Four compound libraries were screened, and hits (right column) were binned into categories (left column) based on biological activities.

One hit, CB 41227199, highlighted the importance of *TGF-β* signaling in PAA angioblast differentiation.

###### Highlights

-   Small-molecule screening implicates TGF-*β* signaling in PAA morphogenesis

-   TGF-*β* inhibition impairs nkx2.5^+^ PAA progenitor differentiation into angioblasts

-   A burst of TGF-*β* signaling activity precedes PAA angioblast differentiation

-   Premature TGF-*β* signaling induction promotes precocious angioblast differentiation
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